Toad-derived resibufogenin blocks NLRP3 inflammasome assembly and shrinks plaques in atherosclerotic mice
In ApoE-/- mice, resibufogenin binds NLRP3 at CYS-279, blocks inflammasome assembly and reduces plaque. Mouse and cell data only.
Summary
Chronic inflammation inside artery walls drives atherosclerosis, and a protein complex called the NLRP3 inflammasome is a key switch for it. Researchers tested resibufogenin (RBG), a compound from traditional toad-secretion medicine, in atherosclerosis-prone ApoE-/- mice on a high-fat diet. RBG-treated mice had smaller plaques, lower body weight and less inflammatory signaling in the aorta. In macrophages, RBG reduced foam cell formation and shifted cells from inflammatory M1 toward repair-type M2. Docking, binding assays and pull-downs suggest RBG attaches to a specific cysteine (CYS-279) on NLRP3 and prevents the complex from assembling. All evidence is from mice and cultured cells; safety, dosing and benefit in people are untested.
Detailed Summary
Atherosclerosis is driven not only by cholesterol but by chronic inflammation in the artery wall. The NLRP3 inflammasome, a protein complex in macrophages, activates caspase-1 and releases IL-1β and IL-18, amplifying plaque inflammation. Statins lower lipids but leave residual inflammatory risk, so direct NLRP3 inhibitors are of interest for healthspan. This study tested resibufogenin (RBG), a bufadienolide from Venenum Bufonis (Chansu), as one.
ApoE-/- mice on a C57BL/6 background ate a high-fat diet for 12 weeks. From week 5, they received daily oral gavage for 8 weeks of saline, rosuvastatin (2.1 mg/kg), RBG at 1, 3 or 5 mg/kg, or the reference NLRP3 inhibitor MCC950 (20 mg/kg). Aorta-specific NLRP3 knockdown (AAV9-shRNA) tested whether the effect depends on NLRP3. Cell work used bone marrow-derived macrophages (BMDMs) and RAW264.7 cells exposed to ox-LDL, LPS/ATP or polarizing cytokines, at 25, 50 and 100 nM RBG.
On function and pathology, RBG reduced body weight, aortic Oil Red O lipid staining and aortic-root plaque size on H&E and Masson staining. It also reduced α-SMA staining, which the authors read as less fibrosis, and improved circulating adhesion molecules, suggesting better endothelial function. Serum lipid effects were described as partial, and the text is ambiguous about direction for several measures, so the lipid claim should be treated cautiously.
On mechanism, aortic RNA-seq (n=3) pointed to the NOD-like receptor and NF-κB pathways. Western blots (n=6) showed lower NLRP3, ASC, ASC oligomerization, NEK7, cleaved caspase-1 and IL-18 in the aorta, with less NLRP3/ASC/caspase-1 co-localization and fewer infiltrating macrophages. In BMDMs, RBG cut ox-LDL foam cell formation, reduced NF-κB nuclear translocation, lowered M1 and raised M2 proportions. No cytotoxicity appeared below 1 μM.
On target engagement, PyMOL identified five exposed cysteines on the NLRP3 NACHT domain. Docking favored CYS-279 (−5.4 kcal/mol), with hydrogen bonding to ARG-147; an R147A mutant docked poorly. Three 500 ns molecular dynamics runs showed a stable complex (RMSD about 3 Å). The abstract reports SPR and pull-down confirmation of a non-covalent interaction, though the supplied text cuts off before those results.
Implication: RBG is a plausible NLRP3-directed anti-inflammatory lead that moved mechanism and plaque pathology in mice. Lifespan was not measured. Still needed are pharmacokinetics, toxicity (bufadienolides are cardiac-active, a concern the authors do not discuss in the supplied text), independent replication and human data. Group sizes for histology were small (n=3).
Key Findings
- Mouse design: ApoE-/- mice on a high-fat diet, RBG gavage at 1, 3 or 5 mg/kg daily for 8 weeks, compared with rosuvastatin and MCC950 arms.
- Function/pathology: RBG lowered body weight (n=10) and reduced aortic lipid staining and aortic-root plaque size (histology n=3 per group).
- Mechanism in vivo: aortic NLRP3, ASC, ASC oligomerization, NEK7, cleaved caspase-1 and IL-18 protein fell with RBG (western blot n=6), with less NLRP3/ASC/caspase-1 co-localization.
- Macrophages: RBG (25-100 nM) reduced ox-LDL foam cell formation, NF-κB nuclear translocation and M1 proportion while raising M2 in BMDMs and RAW cells; no cytotoxicity below 1 μM.
- Target engagement: docking placed RBG at NLRP3 CYS-279 (−5.4 kcal/mol) with ARG-147 hydrogen bonding; 500 ns simulations were stable (RMSD about 3 Å); SPR and pull-down reportedly support binding.
- Caveat on lipids: serum TG, TC, LDL-C and HDL-C changes were described only as partial, and text direction is unclear.
- Not shown: lifespan, human data, safety or toxicity outcomes.
Methodology
Preclinical study in male/female-unspecified ApoE-/- mice (n=10 per group for weight, lipids and ELISA; n=6 for western blots; n=3 for histology, RNA-seq and immunofluorescence), with 8 weeks of oral dosing against vehicle, rosuvastatin and MCC950 controls. Cell experiments used BMDMs and RAW264.7 cells, with AAV9-shRNA NLRP3 knockdown and siRNA. Target binding used docking, 500 ns MD, SPR and biotin-RBG pull-downs. Statistics were one-way ANOVA with LSD or Dunnett post hoc tests; RNA-seq used an unadjusted p<0.05 threshold.
Study Limitations
Evidence comes only from mice and cultured cells, with small n=3 groups for histology and RNA-seq and a lenient unadjusted threshold for differential expression. Several lipid and cytokine results are described ambiguously, and no lifespan, toxicity or cardiac safety data are presented in the supplied text. The authors state safety and efficacy in humans and combinations with other treatments need further study; no conflict of interest statement was supplied.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
